IMA
NASDAQImageneBio Inc.
Price$5.69-0.51 (-8.23%)
2026-03-042026-06-05
News · 26 weeks41-92%
2025-12-142026-06-07
Mix2890d
- SEC Filings13(46%)
- Other9(32%)
- Insider5(18%)
- Offering1(4%)
Latest news
25 items- PRImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkSAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings. Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 10-Q filed by ImageneBio Inc.10-Q - ImageneBio, Inc. (0001835579) (Filer)
- SECImageneBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateSAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds of approximately $30 million led by new investor, Coastlands Capital, with participation from Trails Edge Capital Partners and existing investors Omega Funds and OrbiMed, among others. The financing extends the Company's cash runway into the first quarter of 2028 and enables
- SECSEC Form DEFA14A filed by ImageneBio Inc.DEFA14A - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form DEF 14A filed by ImageneBio Inc.DEF 14A - ImageneBio, Inc. (0001835579) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ImageneBio Inc.SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
- SECSEC Form SCHEDULE 13D filed by ImageneBio Inc.SCHEDULE 13D - ImageneBio, Inc. (0001835579) (Subject)
- INSIDERSEC Form 3 filed by new insider Lally Robert B3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 3 filed by new insider Su Wei-Guo3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Bonita David P4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - ImageneBio, Inc. (0001835579) (Issuer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECImageneBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio Announces $30 Million Private PlacementPrivate placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for the ongoing program in moderate-to-severe atopic dermatitis IMG-007 is the lead receptor-targeting, non-depleting OX40 antagonist in active clinical development SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA)("Imagene" or the "Company") today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million
- SECSEC Form EFFECT filed by ImageneBio Inc.EFFECT - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form POS AM filed by ImageneBio Inc.POS AM - ImageneBio, Inc. (0001835579) (Filer)
- INSIDERSEC Form 4 filed by Yarema Kristin4 - ImageneBio, Inc. (0001835579) (Issuer)
- SECSEC Form 8-K filed by ImageneBio Inc.8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that on March 16, 2026 the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") granted equity awards to two newly hired employees in the form of restricted stock units ("RSUs") and non-qualified stock options ("NSOs") for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The employment inducement awards were granted under the Company's 2025 Inducement Plan. Each NSO has an exercise price equal to $6.20 per share,
- SECSEC Form S-8 filed by ImageneBio Inc.S-8 - ImageneBio, Inc. (0001835579) (Filer)
IMA FAQ
6 questionsWhere does IMA stock trade?
ImageneBio Inc. (IMA) is listed on NASDAQ.What sector and industry is IMA in?
ImageneBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImageneBio Inc. go public?
ImageneBio Inc. (IMA) completed its IPO in 2021.What are analysts saying about IMA?
ImageneBio Inc. has had 2 recent analyst actions on file. The most recent action was from Wedbush: Underperform with a $200.00 price target on 2025-11-25.What companies are similar to IMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IMA side-by-side with any of them on Quantisnow.How can I track IMA on Quantisnow?
Quantisnow aggregates ImageneBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMA to receive live email and push alerts on every new disclosure.